Investors

Corporate News

2016

08 December Appointment of Chief Financial Officer
01 December Appointment of Nominated Adviser
28 November TR-1 Notification of Major Interest in Shares
17 November TR-1 Notification of Major Interest in Shares
15 November TR-1 Notification of Major Interest in Shares
14 November TR-1 Notification of Major Interest in Shares
14 November TR-1 Notification of Major Interest in Shares
14 November TR-1 Notification of Major Interest in Shares
11 November Grant and Waiver of LTIP Options
11 November Director's Dealings
10 November Result of General Meeting & Total Voting Rights
09 November TR-1 Notification of Major Interest in Shares
09 November TR-1 Notification of Major Interest in Shares
21 October Posting of Circular
20 October Confirmation of successful £15 million fundraise subject to shareholder approval
20 October Close of accelerated bookbuild - successful fundraise of £15 million at 34p per share
20 October Proposed Accelerated Bookbuild to raise up to £15 million
19 October CEO appointment and Board Changes
06 October TR-1 Notification of Major Interest in Shares
06 October TR-1 Notification of Major Interest in Shares
05 October TR-1 Notification of Major Interest in Shares
05 October TR-1 Notification of Major Interest in Shares
04 October Half year results for the six months to 31 July 2016
31 August Trading Update
Notice of Half Year Results
25 August TR-1 Notification of Major Interest in Shares
10 August Launch of Glycopyrronium Bromide Oral Solution
05 August Launch of Mucodis® Vaginal Cream
01 August Directorate Change
28 July TR-1 Notification of Major Interest in Shares
26 July Launch of Mucodis® Rectal Gel
19 July Grant of LTIP options and Grant of SAYE options under Greek sub-plan
14 July Grant of SAYE options
12 July Result of Annual General Meeting
12 July AGM Statement and Directorate Change
11 July Launch of Mucodis® Dermal Spray
13 June Annual Report and Accounts
Notice of Annual General Meeting
Retail Investor Days
01 June Class I medical device status for Biodose Connect®
13 May TR-1 Notification of Major Interest in Shares
10 May Final Results
29 April TR-1 Notification of Major Interest in Shares
19 April Launch of Ergocalciferol 50,000 IU capsules
12 April Marketing Authorisations (product licences) received for Aviticol™ and Colecalciferol 800 IU and 1000 IU Capsules
04 April Appointment of Joint Broker
01 April Award of Contract Extension from AAH Pharmaceuticals
11 March Directors Share Purchase and Options Grant
08 March Appointment of Chief Financial Officer
02 February Presentation at the Innovators & Investors Forum 2016
29 January TR-1 Notification of Major Interest in Shares
25 January Second Mucodis® Medical Device Launch
19 January Trading Update

 

 
Quantum Pharmaceuticals
UL Medicines
Quantum Aseptics
PERN Consumer Products
Biodose Intelligent Medication Management